Welcome to our dedicated page for Achieve Life Sciences news (Ticker: ACHV), a resource for investors and traders seeking the latest updates and insights on Achieve Life Sciences stock.
Achieve Life Sciences reports company news around the development and potential commercialization of cytisinicline, an investigational treatment for nicotine dependence. Cytisinicline is a plant-based alkaloid that binds to nicotinic acetylcholine receptors and is being studied for smoking cessation and e-cigarette cessation; it has not been approved by the FDA for any indication in the United States.
Recurring ACHV updates include financial results, clinical data presentations, regulatory and manufacturing progress, supply-chain arrangements for cytisinicline, capital-structure actions, and governance changes. Company announcements also cover scientific publications, board and executive appointments, and operational steps tied to preparing the cytisinicline program for potential commercial use if regulatory approval is obtained.
Achieve Life Sciences (Nasdaq: ACHV) announced successful topline results from the RAUORA Phase 3 trial, comparing cytisinicline to varenicline for smoking cessation. Conducted in New Zealand, the trial involved 679 participants and demonstrated that cytisinicline was at least as effective as varenicline, with significantly fewer adverse effects. The trial results suggest a promising future for cytisinicline in addressing nicotine addiction, especially among Māori populations. Full results are expected to be presented at the SRNT-E Annual Meeting in September 2020.